Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been given an average rating of “Moderate Buy” by the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $42.6429.

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Viridian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, February 4th. Royal Bank Of Canada raised their price objective on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Wedbush upped their target price on Viridian Therapeutics from $42.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Finally, Wells Fargo & Company increased their price objective on Viridian Therapeutics from $26.00 to $29.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd.

Viridian Therapeutics Stock Down 3.0%

Shares of Viridian Therapeutics stock opened at $27.90 on Tuesday. The firm has a market cap of $2.66 billion, a P/E ratio of -9.24 and a beta of 0.98. Viridian Therapeutics has a fifty-two week low of $9.90 and a fifty-two week high of $34.29. The business has a 50-day moving average price of $31.71 and a 200 day moving average price of $25.80. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.07.

Insider Activity

In other news, insider Jennifer Tousignant sold 2,272 shares of the firm’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total value of $70,795.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.65% of the company’s stock.

Institutional Investors Weigh In On Viridian Therapeutics

Large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after purchasing an additional 876 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Viridian Therapeutics by 33.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after purchasing an additional 310,998 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Viridian Therapeutics by 12.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after buying an additional 14,788 shares during the period. TD Asset Management Inc raised its position in shares of Viridian Therapeutics by 174.8% during the 2nd quarter. TD Asset Management Inc now owns 89,600 shares of the company’s stock valued at $1,253,000 after acquiring an additional 57,000 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Viridian Therapeutics in the second quarter valued at about $180,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.